Target intelligence / Profile preview

Cytochrome b558 (gp91phox-p22phox complex) (Cyt b558)

Target
Cyt b558
Molecular classification
Enzyme, Oxidoreductase, Membrane protein complex, Flavoprotein, Heme protein
01

Overview

The gp91phox-p22phox membrane flavocytochrome complex, commonly known as Cytochrome b558, is the catalytic core of the phagocyte NADPH oxidase (NOX2) system. It is a heterodimeric integral membrane protein consisting of a large glycosylated subunit (gp91phox or NOX2) and a smaller subunit (p22phox or CYBA). Upon activation, this complex recruits cytosolic regulatory proteins to transfer electrons from NADPH to molecular oxygen, generating superoxide anions as part of the respiratory burst essential for microbial killing (UniProt P04839, P13498). Mutations in either subunit lead to Chronic Granulomatous Disease (CGD), characterized by severe recurrent infections and granuloma formation due to the inability of phagocytes to produce reactive oxygen species (PubMed: 25222463). In addition to its role in host defense, overactivation of the complex is implicated in oxidative stress-related pathologies such as atherosclerosis, hypertension, and neurodegeneration (PubMed: 29038200). Therapeutic strategies targeting this complex aim to modulate ROS production, though selectivity remains a challenge to avoid compromising the innate immune response.

Other names
Flavocytochrome b558NADPH oxidase 2 complexNOX2-p22phox complexgp91phox-p22phox heterodimerPhagocyte NADPH oxidase
02

Mechanism of action

Inhibition of electron transfer from NADPH to molecular oxygen, preventing the formation of superoxide radicals; disruption of the assembly of cytosolic subunits (p47phox, p67phox, p40phox) with the membrane-bound cytochrome b558 complex.

03

Biological functions

Superoxide anion generationRespiratory burstInnate immune responseReactive oxygen species (ROS) productionPhagocytosisRedox signaling
04

Disease associations

Chronic Granulomatous Disease (CGD)InflammationCardiovascular diseaseNeurodegenerative diseaseIschemia-reperfusion injuryAutoimmune disorders
05

Safety considerations

ImmunosuppressionIncreased susceptibility to bacterial and fungal infectionsImpaired wound healingOff-target inhibition of other NOX isoformsPotential for granuloma formation
06

Interacting drugs

DPI (Diphenyleneiodonium)

4 more in the full profile.

07

Biomarkers

Nitroblue tetrazolium (NBT) reductionDihydrorhodamine 123 (DHR) flow cytometrySuperoxide dismutase-inhibitable ferricytochrome c reductionChemiluminescence (Lucigenin/Luminol)

Beyond the preview

Go deeper on Cytochrome b558 (gp91phox-p22phox complex) (Cyt b558).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome b558 (gp91phox-p22phox complex) (Cyt b558).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call